2024
Participant Diversity in United States Randomized Controlled Trials of Antibacterials for Staphylococcus aureus Infections, 2000–2021
Kwon J, Pelletiers W, Peña J, van Duin D, Ledbetter L, Baum K, Ruffin F, Knisely J, Bizzell E, Fowler V, Chambers H, Pettigrew M. Participant Diversity in United States Randomized Controlled Trials of Antibacterials for Staphylococcus aureus Infections, 2000–2021. Clinical Infectious Diseases 2024, 79: 141-147. PMID: 38306502, PMCID: PMC11259209, DOI: 10.1093/cid/ciae049.Peer-Reviewed Original ResearchMethicillin-resistant S. aureusRandomized Controlled TrialsPhase 2/3 trialsPhase 4 trialIncidence of methicillin-resistant S. aureusTreat Staphylococcus aureus infectionsStaphylococcus aureus infectionStandard of carePercentage of study participantsIncidence ratiosClinical trialsEthnicity of participantsControlled TrialsStandardized reporting methodsBlack participantsStudy sizeInfectionDisease populationTrialsStudy participantsAntibacterial agentsIncreased recruitmentIndustry sponsorshipEthnicity dataSex
2021
Research abuses against people of colour and other vulnerable groups in early psychedelic research
Strauss D, de la Salle S, Sloshower J, Williams MT. Research abuses against people of colour and other vulnerable groups in early psychedelic research. Journal Of Medical Ethics 2021, 48: 728-737. PMID: 34253622, DOI: 10.1136/medethics-2021-107262.Peer-Reviewed Original ResearchSubstance use disordersDrug administration conditionsPsychedelic researchMental health issuesEthnicity of participantsUse disordersMental healthHealth issuesVulnerable populationsPsychedelic medicineVulnerable groupsResearch abusesFuture studiesAdministration conditionsAbuseCurrent ethical standardsFirst waveVariables of interestParticipantsFindings
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply